Uses of t cell engaging proteins in the treatment of cancer
A body-weight-tailored dosing regimen for T cell engaging proteins targeting CD3 and DLL3 in neuroendocrine neoplasms allows for higher, safer doses, overcoming treatment limitations and side effects in current therapies.
Patent Information
- Application Number
- PCT/EP2024/063678
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-28
AI Technical Summary
Current treatments for neuroendocrine neoplasms, such as small cell lung cancer and glioma, are ineffective in achieving long-term remission and are associated with significant side effects like cytokine release syndrome, limiting the dosage of T cell engaging proteins that can be administered.
A dosing regimen for T cell engaging proteins that specifically bind to CD3 and DLL3, involving a step-in cycle with initial, elevated, and further doses tailored to the patient's body weight, allowing for higher doses while minimizing adverse effects like cytokine release syndrome.
This approach enables unprecedented high doses of T cell engaging proteins to be administered safely, reducing side effects and achieving clinical responses while avoiding severe adverse events.
Smart Images

Figure IMGF000048_0001 
Figure IMGF000049_0001 
Figure IMGF000054_0001
Abstract
Citation Information
Patent Citations
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
WO1990005144A1
Cytotoxicity-inducing therapeutic agent
WO2019131988A1
DLL3-CD3 bispecific antibodies
WO2019234220A1
DLL3 binding proteins and methods of use
WO2020069028A1
DLL3-targeting multispecific antigen-binding molecules and uses thereof
WO2021200898A1
